Patent ID: 6627728
Filing Date: 2003-09-30
Classification: A61K,C07K

Abstract:
An isolated polypeptide comprising a member selected from the group consisting of(a) a amino acid sequence matching one of SEQ ID NOs:2, 4, or 6; and (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids that matches an aligned contiguous segment of one of SEQ ID NOs: SEQ ID NOs:2, 4, or 6; selected from the following contiguous segments thereof: 1-15; 2-16; 3-17; 4-18; 5-19; 6-20; 7-21; 8-22; 9-23; 10-24; 11-25; 12-26; 13-27; 14-28; 15-29; 16-30; 17-31; 18-32; 19-33; 20-34; 21-35; 22-36; 23-37; 24-38; 25-39; 26-40; 27-41; 28-42; 29-43; 30-44; 31-45; 32-46; 33-47; 34-48; 35-49; 36-50; 37-51; 38-52; 39-53; 40-54; 41-55; 42-56; 43-57; 44-58; 45-59; 46-60; 47-61; 48-62; 49-63; 50-64; 51-65; 52-66; 53-67; 54-68; 55-69; 56-70; 57-71; 58-72, 59-73; 60-74; 61-75; 62-76; 63-77; 64-78; 65-79; 66-80; 67-81; 68-82; 69-83; 70-84; 71-85; 72-86; 73-87; 74-88; 75-89; 76-90; 77-91; 78-92; 79-93; 80-94; 81-95; 82-96; 83-97; 84-98; 85-99; 86-100; 87-101; 88-102; 89-103; 90-104; 91-105; 92-106; 93-107; 94-108; 95-109; 96-110; 97-111; 98-112; 99-113; 100-114; 101-115; 102-116; 103-117; 104-118; 105-119; 106-120; 107-121; 108-122; 109-123; 110-124; 111-125; 112-126; 113-127; 114-128; 115-129; 116-130; 117-131; 118-132; 119-133; 120-134; 121-135; 122-136; 123-137; 124-138; 125-139; 126-140; 127-141; 128-142; 129-143; 130-144; 131-145; 132-146; 133-147; 134-148; 135-149; 136-150; 137-151; 138-152; 139-153; 140-154; 141-155; 142-156; 143-157; 144-158; 145-159; 146-160; 147-161; 148-162; 149-163; 150-164; 151-165; 152-166; 153-167; 154-168; 155-169; 156-170; 157-171; 158-172; 159-173; 160-174; 161-175; 162-176; 163-177; 164-178; 165-179; 166-180; 167-181; 168-182; 169-183; 170-184; 171-185; 172-186; 173-187; 174-188; 175-189; 176-190; 177-191; 178-192; 179-193; 180-194; 181-195; 182-196; 183-197; 184-198; 185-199; 186-200; 187-201; 188-202; 189-203; 190-204; 191-205; 192-206; 193-207; 194-208; 195-209; 196-210; 197-211; 198-212; 199-213; 200-214; 201-215; 202-216; 203-217; 204-218; 205-219; 206-220; 207-221; 208-222; 209-223; 210-224; 211-225; 212-226; 213-227; 214-228; 215-229; 216-230; 217-231; 218-232; 219-233; 220-234; 221-235; 222-236; 223-237; 224-238; 225-239; 226-240; 227-241; 228-242; 229-243; 230-244; 231-245, 232-246; 233-247; 234-248; 235-249; 236-250; 237-251; 238-252; 239-253; 240-254; 241-255; 242-256; 243-257; 244-258; 245-259; 246-260; 247-261; 248-262; 249-263; 240-264; 251-265; 252-266; 253-267; 254-268; 255-269; 256-270; 257-271; 258-272; 259-273; 260-274; 261-275; 262-276; 263-277; 264-278; 265-279; 266-280; 267-281; 268-282; 269-283; 270-284; 271-285; 272-286; 273-287; 274-288; 275-289; 276-290; 277-291; 278-292; 279-293; 280-294; 281-295; 282-296; 283-297; 284-298; 285-299; 286-300; 287-301; 288-302; 289-303; 290-304; 291-305; 292-306; 293-307; 294-308; 295-309; 296-310; 297-311; 298-312; 299-313; 300-314; 301-315; 302-316; 303-317; 304-318; 305-319; 306-320; 307-321; 308-322; 309-323; 310-324; 311-325; 312-326; 313-327; 314-328; 315-329; 316-330; 317-331; 318-332; 319-333; 320-334; 321-335; 322-336; 323-337; 324-338; 325-339; 326-340; 327-341; 328-342; 329-343; 330-344; 331-345; 332-346; 333-347; 334-348; 335-349; 336-350; 337-351; 338-352; 339-353; 340-354; 341-355; 342-356; 343-357; 344-358; 345-359; 346-360; 347-361; 348-362; 349-363; 350-364; 351-365; 352-366; 353-367; 354-368; 355-369; 356-370; 357-371; 358-372; 359-373; 360-374; 361-375; 362-376; 363-377; 364-378; 365-379; 366-380; 367-381; 368-382; 369-383; 370-384; 371-385; 372-386; 373-387; 374-388; 375-389; 376-390; 377-391; wherein the isolated polypeptide, when administered to a subject in a composition which can include an adjuvant, or a carrier coupled to the polypeptide, induces an antibody or T-cell immune response to a polypeptide having the sequence of one of SEQ ID NOs:2, 4, or 6.